Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis
Journal of Clinical Medicine · 14.06.2026 · 15 (12) · 4622
DOI: 10.3390/jcm15124622 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.06.2026. Verfasst von Sarayu Balachandar und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Several novel biologics and small-molecule therapies have emerged for the treatment of antihistamine-refractory chronic spontaneous urticaria (CSU), yet no study has directly compared their speed of response. This study aims to provide indirect evidence on the relative time to meaningful clinical response across approved and investigational therapies using a Bayesian network meta-analysis.
Methods
Phase 2 and phase 3 randomized controlled trials reporting UAS7 scores in a graphical format for antihistamine-refractory CSU were included. The primary outcome was the mean time in weeks to minimal clinically important difference (MCID), defined as a UAS7 reduction of 10 points. Data were extracted using WebPlotDigitizer (v4.7) and analyzed via Bayesian random-effects network meta-analysis in MetaInsight (v6.4.0), with placebo as the reference node.
Results
All drugs except rilzabrutinib 400 mg daily demonstrated faster mean time to MCID than placebo. Fenebrutinib had the fastest mean time to MCID (0.67–0.76 weeks), and tezepelumab the slowest (5.41–5.65 weeks). Only omalizumab 300 mg every 4 weeks, dupilumab 300 mg every 2 weeks, and ligelizumab 72 mg and 120 mg every 4 weeks achieved statistically significant reductions compared with placebo. All treatments had wide credible intervals reflecting limited direct comparisons.
Conclusions
This is the first network meta-analysis comparing time to meaningful symptom control across therapies for antihistamine-refractory CSU. Omalizumab, dupilumab, and ligelizumab demonstrated statistically significant reductions in time to MCID compared with placebo. Head-to-head trials with standardized outcome reporting would enable more definitive comparative conclusions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
- Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
ORCID-Profile: Sarayu Balachandar, Dylan R Clapp, Alan B Fleischer
Zitieren
APA
Balachandar, S., Clapp, D. R., & Fleischer, A. B. (2026). Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis. Journal of Clinical Medicine, 15(12), 4622. https://doi.org/10.3390/jcm15124622
Vancouver
Balachandar S, Clapp DR, Fleischer AB. Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis. Journal of Clinical Medicine. 2026;15(12):4622. doi:10.3390/jcm15124622
BibTeX
@article{Balachandar2026,
author = {Balachandar, Sarayu and Clapp, Dylan R and Fleischer, Alan B},
title = {Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4622},
doi = {10.3390/jcm15124622}
}
EUVIMED